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We previously reported that antiestrogen-liganded estro-
gen receptor b (ERb) transcriptionally activates the major
detoxifying enzyme quinone reductase (QR) (NAD(P)H:-
quinone oxidoreductase). Our studies also indicate that
upregulation of QR, either by overexpression or induction
by tamoxifen, can protect breast cells against oxidative
DNA damage caused by estrogen metabolites. We now
report on the upregulation of glutathione S-transferases
Pi (GST-Pi) and gamma-glutamylcysteine synthetase
heavy subunit (GCSh) expression by antiestrogens.
Studies indicate the regulation of GST-Pi and GCSh
transcriptional activity by ER. While ER regulation is
mediated by an electrophile response element (EpRE), we
identified mechanistic differences in the involvement of
other transcription factors. Regardless of these differ-
ences, ERb-mediated regulation of GST-Pi and GCSh
point towards an important role for ERb in cellular
protection against oxidative stress. A protective role is
supported by our observation of inhibition of estrogen-
induced DNA damage upon upregulation of GST-Pi and
GCSh expression.
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Phase 2 detoxification enzymes such as NAD(P)H:(qui-
none-acceptor) oxidoreductase (quinone reductase
(QR)), glutathione S-transferases (GSTs), epoxide hy-
drolase, and UDP-glucuronosyltransferases are induced
in cells by electrophilic compounds and phenolic
antioxidants (reviewed in Talalay, 1989; Prestera et al.,
1993). These widely distributed enzymes detoxify
electrophiles, thereby protecting cells against the toxic
and neoplastic effects of carcinogens. We have pre-
viously shown that increases in QR enzyme activity can
be induced by low concentrations of antiestrogens in
breast cancer cells (Montano and Katzenellenbogen,
1997). Induction of QR enzymatic activity showed
unusual reversed pharmacology, being markedly upre-
gulated by antiestrogen and suppressed by estrogen in
breast cancer cells. The antiestrogen regulation of QR
enzymatic activity represents a potentially important
pharmacological mechanism for this group of anticancer
drugs that had not been previously recognized.
The electrophile response element (EpRE, also
referred to as antioxidant response element, ARE) motif
has been identified in the regulatory region of the gene
encoding QR (reviewed in Jaiswal, 2000). This element
has been shown to mediate basal expression and its
activation by phenolic antioxidants, and it appears to be
essential for antiestrogen stimulation (Montano and
Katzenellenbogen, 1997). Since the EpRE is involved in
the regulation of other genes encoding proteins involved
in the protection against oxidative stress, we examined if
these genes can also be regulated by estrogen receptor
(ER) and its ligands. For these studies, we chose two
genes in particular that encode antioxidative stress
enzymes, glutathione S-transferase Pi (GST-Pi) and
gamma-glutamylcysteine synthetase heavy subunit
(GCSh). The functions of which are interrelated as will
be discussed below.
The nonprotein thiol, glutathione (gamma-glutamyl-
cysteinyl-glycine, GSH) is a predominant cellular anti-
oxidant (reviewed in Griffith and Mulcahy, 1999). As
such GSH serves critical functions in the maintenance of
cellular redox balance and provides protection against
reactive oxygen species. GSH is involved in the
detoxication of xenobiotics either through direct reac-
tions with reactive intermediates or via enzymatic
conjugation reactions catalysed by GSTs. Exposure of
cells to a number of xenobiotic agents results in a
significant increase in the total intracellular GSH
content. This is due to transcriptional upregulation of
the genes encoding the two protein subunits (catalytic
(heavy) and regulatory (light)) of gamma-glutamylcys-
teine synthetase (GCS), the rate-limiting enzyme in its de
novo synthesis. It is hypothesized that transcriptional
upregulation of the two GCS subunit genes involves
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similar cis-elements, but distinct combinations of trans-
acting factors, contributing to differential regulation in
response to specific inducting agents (Mulcahy et al.,
1997; Moinova and Mulcahy, 1998). Transcription is
hypothesized to involve dimeric transcription factors
composed of small Maf proteins and various other bZIP
family members, including NFE-2-related factor 1 and 2
(NRF1 and NRF2) (Wild et al., 1999).
GST is a family of enzymes that catalyses the
conjugation of electrophilic compounds with glu-
tathione (reviewed in Strange et al., 2001). This resulting
complex is less toxic and more readily excreted. The
GST gene family is extensive, with distinct isozymes
expressing different functional properties. The family is
characterized by promiscuous substrate specificity with
low ‘catalytic efficiency’, characteristics integral to the
evolution of GSTs as detoxifiers of a broad spectrum of
endogenous and environmental chemicals. GST-P1-1,
the only representative of the GST-Pi family of enzymes,
is the most prevalent isozyme in nonhepatic tissues.
The transcription factors Fos and Jun have been
proposed to functionally interact and bind to promoter
elements at the GST-Pi gene promoter (Moffat et al.,
1994, 1996).
Antiestrogen upregulation of QR expression is
reflected at the transcriptional level and requires the
ER. Interestingly estrogen receptor b (ERb) is a more
potent activator of QR gene transcriptional activity than
estrogen receptor b (ERa) (Montano et al., 1998). Gel
shift assays suggest that antiestrogen-mediated induc-
tion of QR gene transcriptional activity in MCF7 cells
involves a direct transcriptional effect where ERa or
ERb are components of the protein complex that binds
the EpRE. Our studies indicate that the regulation by
antiestrogen-liganded ER may also be attributable to
changes in the levels and/or the activity of other factors
(Montano et al., 2000) Supporting the involvement of
other protein factors is that the same receptor isoform
bound to the same ligand can have different transcrip-
tional activities dependent on the enhancer element
(ERE vs EpRE, Montano et al., 1998). Unraveling these
additional EpRE binding proteins and how they affect
ER binding and transcriptional activity are crucial for
understanding how antiestrogen-bound ER causes
upregulation of these genes. Thus, studies were con-
ducted to further dissect the molecular mechanism(s)
involved in antiestrogen induction of the GST-Pi and
GCSh EpRE by identifying other transcriptional factors
involved in this regulation. In addition, a biological
readout for transcriptional regulation of GST-Pi and
GCSh by antiestrogens was established by examining
its role in the inhibition of estrogen-induced DNA
damage.
We now report on the upregulation of GST-Pi and
GCSh expression by antiestrogens. Studies indicate the
regulation of GST-Pi and GCSh transcriptional activity
by ERb. While ERb regulation is mediated by an EpRE
element, we identified mechanistic differences in the
involvement of other transcription factors. Regardless
of these differences, functional studies on ERb-mediated
regulation of GST-Pi and GCSh point towards an
important role for ERb in cellular protection against
oxidative stress.
Results
Upregulation of GST-Pi and GCSh expression
and transcriptional activity by estradiol
and trans-hydroxytamoxifen (TOT)
Using Northern blot analyses, we observed an average
1.9-fold increase in GST-Pi mRNA expression after
tamoxifen treatment. (Figure 1a). The increase in GST-
Pi expression in response to tamoxifen is also evident at
the protein level wherein we observe an average ninefold
increase (Figure 1b). GCSh mRNA expression was
upregulated in MCF7 cells after estrogen (average 2.5-
fold) and tamoxifen (average threefold) treatment
(Figure 1a). GCSh protein expression was also upregu-
lated by estrogens (average 2.6-fold) and antiestrogens
(average 5.4-fold) (Figure 1b).
To determine if estrogen and antiestrogen regulation
of GST-Pi expression occurs at the transcriptional level,
a luciferase reporter construct containing 242/þ 85
GST-Pi gene promoter region was transfected into
breast epithelial MDA-MB-231 cells along with an
expression vector for ERa or ERb. It has been
previously reported that the proximal promoter at
130/41 has the elements necessary for optimal
expression (Jhaveri and Morrow, 1998a, b). This region
also contains a putative EpRE element. Our analyses of
reporter activity revealed an increase in GST-Pi gene
transcriptional activity in response to TOT (Figure 2a),
with stronger activation observed with ERb than with
ERa. While we observe an increase in reporter activity in
Figure 1 Increased expression of GST-Pi and GCSh in response
to estradiol and trans-hydroxytamoxifen. (a) Northern blot
analyses of mRNA from MCF7 cells treated with control ethanol
vehicle (c), 17b-estradiol (E2, 108M), or trans-hydroxytamoxifen
(TOT, 107M) for 24 h. The autoradiographs are representative of
three separate experiments. (b) Western blot analyses of GST-Pi
and GCSh protein levels in MCF7 cells in the presence of vehicle
(c), E2 (10
8 M), or TOT (107M). Whole cell lysates were collected
24 h after treatment, electrophoresed on SDS–PAGE gels, trans-
ferred to nitrocellulose filters, probed with GST-Pi or GCSh
antibody, and visualized using horseradish peroxidase-conjugated
secondary antibody. The lower panels show the blots probed with
cytokeratin 18 to show equal loading. The autoradiographs are
representative of three separate experiments
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response to 17b-estradiol (E2), the increase was not
statistically significant.
A luciferase reporter construct containing the 3.8kb
50flanking region of the GCSh gene promoter was
introduced into MDA-MB-231 cells. An increase in
transcriptional activity of the GCSh-pGL3 reporter
construct in the presence of E2 and TOT was observed
in MDA-MB-231 cells when cells were cotransfected with
an expression vector for ERb (Figure 2b). The induction
of GST-Pi-pGL3 and GCSh-pGL3 activities appears to be
mediated by the ER because no induction was observed in
cells transfected with an empty expression vector. No
increase in the activity of the control pGL3 promoter
vector was observed with E2 or TOT (data not shown).
Identification of GST-Pi and ERb GCSh gene promoter
regions and transcription factors involved in the activation
by the ER
An EpRE core sequence G/CTGA(C/G)nnnGC(A/G)
can be localized at 70 to 60 bp of the GST-Pi gene
promoter. This putative EpRE also contains a putative
AP1 site. In addition, an NF-kB site, distal GC box, and
proximal GC box have been identified at the 125/
33 bp region of the GST-Pi gene promoter (Jhaveri
and Morrow, 1998a, b). To ascertain the involvement of
the putative EpRE in ERb-mediated activation of the
GST-Pi gene promoter, we performed deletional and
mutational analyses of the 125/33 bp region of the
GST-Pi gene promoter. Removal of the NF-kB site (at –
98/89) decreased basal reporter activity, but ERb
activation was still evident (Figure 3a). Mutations of the
EpRE/TRE, distal GC (Sp1 element), and proximal GC
box (Sp1 element) significantly decreased promoter
activity; however TOT induction of GST-Pi gene
promoter activity was still evident after mutations of
the distal and proximal GC box (Figure 3b). No
induction with TOT was apparent after mutation of
the putative EpRE/AP1 site. A luciferase reporter vector
wherein the EpRE was introduced upstream of a
heterologous thymidine kinase (tk) gene promoter was
also activated by TOT (Figure 3b). Upon mutation of
the proximal GC box, we observed a more significant
activation by E2, suggesting that this element may have
a repressive effect on E2 activation. While the mechan-
ism for the activation by estrogens is beyond the scope
of this manuscript, Sp1 transcription factors have been
shown to have both positive and inhibitory crosstalk
with nuclear receptor-mediated transcription (reviewed
in Safe, 2001; Zhang and Dufau, 2003).
An EpRE core sequence has been previously localized
to 3.1 kb from the transcriptional start site of the
GCSh gene promoter (Mulcahy et al., 1997). This EpRE
was introduced upstream of the tk gene promoter cloned
into the pGL3 vector to make EpREGCSh-tk-pGL3.
After cotransfection of reporter into MDA-MB-231
cells, increased reporter activity was observed with both
estrogen and tamoxifen (Figure 3c). Upon mutation of
the EpRE core sequence, no induction was evident with
either estrogen or tamoxifen (Figure 3c).
We then examined the effects of other transcription
factors on EpRE enhancer activity. The two EpREs
behaved similarly to the EpRE identified in the QR gene
promoter as activation was observed with other factors
previously identified to activate QR EpRE enhancer
activity, NRF2 and hPMC2 (Figures 4a and b). The level
of induction observed with ERb was comparable to
NRF2, which has been previously shown to upregulate
GCSh EpRE enhancer activity. AP-1 transcription
factors have been previously reported to bind to the
GST-Pi EpRE (Moffat et al., 1994, 1996). However, this
does not appear to result in transactivation as Jun, Fos,
or Jun and Fos together did not activate GST-Pi or GCSh
EpRE activity (Figure 4). As a control, Fos and Jun are
shown in Figure 4c as capable of activating a luciferase
reporter containing AP1 consensus binding sites.
Figure 2 Regulation of GST-Pi and GCSh gene promoter activity
by the ER. MDA-MB-231 cells were transfected with the (a) GST-
Pi gene or (b) GCSh gene promoter reporter constructs along with
control expression vector (no ER, 100 ng) or expression vector for
ERb (100 ng), or ERb (100 ng). Cells were also transfected with
PRL-SV40/Luc internal control reporter to correct for transfection
efficiency. Cells were then treated for 24 h with vehicle (c), E2
(108M), or TOT (107 M) as indicated. Cell extracts were prepared
and analysed for luciferase activity using firefly and Renilla
luciferin substrate. The ratio of firefly to Renilla luciferase activity
was calculated, and reporter activity in cells transfected with
control expression vector (no ER) is set at 1. Values are the
means7s.e. from three or more separate experiments. * denotes
level of significance Po0.05 versus control as determined by t-test
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The involvement of NRF2 and AP1 in ERb-mediated
regulation of EpRE activity was examined using
dominant negative mutant NRF2 or Fos, respectively.
We utilized amounts of FosDNM and NRF2DNM
expression vector that did not influence basal reporter
activity. The amount of FosDNM used was able to inhibit
Fos activation of AP1 reporter (data not shown). As
shown in Figure 5, both NRF2DNM and FosDNM
Figure 4 Regulation of GST-Pi and GCSh EpRE activity by other
activators of EpRE activity. MDA-MB-231 cells were transfected
with (a) EpREGST-Pi-tk-pGL3 or (b) EpREGCSh-tk-pGL3 along
with expression vectors for NRF2, Fos, and Jun, or hPMC2. In (c),
MDA-MB-231 cells were transfected with AP1-luciferase reporter
constructs along with indicated amounts each of Fos and Jun
expression vectors. As a control, cells were treated with 107 M of
the phorbol ester TPA. In (a)–(c), cells were also transfected with
PRL-SV40/Luc internal control reporter to correct for transfection
efficiency. Cell extracts were prepared and analysed for luciferase
activity using firefly and Renilla luciferin substrate. The ratio of
firefly to Renilla luciferase activity was calculated, and reporter
activity in cells transfected with control expression vector is set at 1.
Values are the means7s.e. from three or more separate experi-
ments. * denotes level of significance Po0.01 versus control as
determined by t-test
Figure 3 ER-mediated regulation of GST-Pi and GCSh gene
promoter activity can be localized to the EpRE. (a) 134/þ 45 or
83/33-GST-Pi gene promoter reporter constructs were trans-
fected into MDA-MB-231 cells along with an expression vector for
ERb (100 ng). * denotes level of significance Po0.05 versus control
as determined by t-test. (b) Wild-type or mutant 83/33-GST-Pi,
or reporter construct containing the putative EpRE upstream of
the tk gene promoter were transfected into MDA-MB-231 cells
along with an expression vector for ERb (100 ng). * denotes level of
significance Po0.05 versus control as determined by t-test. (c)
Reporter constructs containing wild-type or mutant GCSh EpRE
upstream of the tk gene promoter were transfected into MDA-MB-
231 cells along with an expression vector for ERb (100 ng).
* denotes level of significance Po0.01 versus control as determined
by t-test. In (a)–(c), cells were treated for 24 h with control ethanol
vehicle (c), E2 (10
8 M), or TOT (107M) as indicated. Cell extracts
were prepared and analysed for luciferase activity using firefly and
Renilla luciferin substrate. The ratio of firefly to Renilla luciferase
activity was calculated. For each wild-type and mutant reporter
construct, reporter activity is reported as fold induction over
reporter activity in cells transfected with wild-type reporter and
control expression vector (no ER) is set at 1. Each value represents
the mean of three or more separate determinations7s.e.m.
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inhibited ERb-mediated activation of GST-Pi EpRE
activity, while only NRF2DNM inhibited activation of
GCSh EpRE activity. Our results indicate that while
Fos appears to be involved in ERb regulation of GST-Pi
EpRE, this does not appear to be the case for the GCSh
EpRE (Figure 5). However, NRF2 appears to be
involved in activation of both the GST-Pi and GCSh
EpRE. These results suggest differential requirement for
other transcription factors, dependent upon the EpRE
and/or its flanking sequences, for ERb activation.
Biochemical analyses of ERb binding to GST-Pi
and GCSh EPRE
Gel shift assays were then conducted to determine if
ERb is part of the DNA–protein complex(es) that bind
to the EpRE site. 32P-end-labeled GST-Pi EpRE or
GCSh EpRE were incubated with MCF7 nuclear
extracts or in vitro translated Fos, Jun, Nrf2, and/or
purified recombinant ERb. A representative autoradio-
graph in Figure 6a shows a GST-Pi EpRE–protein
complex that can be competed out by EpRE and AP1
oligonucleotides and ERb and NRF2 antibodies, but
not a nonspecific IgG. This suggests that ERb, AP1, and
NRF2 transcription factors form a protein complex on
the GST-Pi EpRE. Further studies indicate that ERb
alone did not bind to the EpRE (Figure 6b). While no
band shift was observed with either in vitro translated
Fos or Jun (data not shown), a DNA–protein complex
(SB) was observed when both Fos and Jun were added
to the reaction. The intensity of the band was stronger in
the presence of ERb. The specificity of the DNA–
protein interactions was verified using competitive gel
shift assays with unlabeled GST-Pi EpRE. We also
observed competition by unlabeled AP1 and ERE,
suggesting the presence of Fos, Jun, and ER in the
DNA–protein complex. In addition, the DNA–protein
complex was competed out by ERb antibody, suggesting
that ERb interacts with Fos and/or Jun on the GST-Pi
EpRE. Thus, while Fos and Jun do not directly activate
GST-Pi EpRE, it may be involved in the recruitment of
other factors, such as ERb, that can activate the EpRE.
A DNA–protein complex was also observed in the
presence of ERb and NRF2 that can be competed out
with either ERb or NRF2 antibodies. This observation
suggests interactions between ERb and NRF2 on the
GST-Pi EpRE as well. No binding by Fos and Jun, or
ERb with Fos and Jun were evident upon mutation of
the EpRE (data not shown).
Gel shift assays using MCF7 nuclear extracts along
with the GCSh EpRE also suggest the presence of AP1,
ERb, and NRF2 in a protein complex bound to the
EpRE (Figure 6c). However, our studies also suggest
that Fos and Jun do not interact with ERb on the EpRE
(Figure 6d). No appreciative binding of ERb was
evident with GCSh EpRE, but a DNA–protein complex
was observed in the presence of ERb and NRF2 that can
be competed out with either ERb or NRF2 antibodies.
Thus NRF2, but not Fos and Jun, may interact with
ERb on the GCSh EpRE. Neither NRF2 nor hPMC2
interact with Fos and Jun on the GCSh or GST-Pi
EpRE. This is based on gel shift assays wherein the
AP1–DNA complex (complex A, Figure 6b and d) was
not competed out by NRF2 antibody, and the NRF2–
EpRE complex (complex B, Figure 6b and d) was not
competed out by AP1 oligonucleotides.
Role of GST-Pi and GCSh in the protection against
estrogen-induced DNA damage
We have previously reported that physiological concen-
trations of E2 cause oxidative DNA damage (as
measured by levels of 8-hydroxydeoxyguanine, 8-OH-
dG) in breast epithelial cells, which is dependent upon
estrogen metabolism (Bianco et al., 2003). TOT and the
pure antiestrogen ICI-182,780 protected against E2-
mediated damage in MCF7 cells containing ERb. This is
most likely due to the ability of these antiestrogens to
activate expression of QR via ERb. Consistent with this
is our observation that levels of 8-OH-dG were inversely
correlated to QR and ERb levels. However, our studies
indicate that QR may not be the only antioxidative
stress enzyme involved in this protective effect. We thus
examined if GST-Pi or GCSh can protect against E2-
induced DNA damage.
We used retroviral infection to modulate GST-Pi and
GCSh levels in MCF7 cells, and changes in protein
levels were demonstrated using immunofluorescence
staining (Figure 7a). Consistent with our previous
studies, we see upregulation of 8-OH-dG with E2
treatment, and inhibition of E2-induced DNA damage
by TOT (Figure 7b). Upregulation of GST-Pi (average
75% increase) or GCSh (average 83% increase) levels
Figure 5 Role of NRF2 and Fos transcription factors in ERb-
mediated activation of EpRE enhancer activity. MDA-MB-231
cells were transfected with EpREGST-Pi-tk-pGL3 or EpREGCSh-tk-
pGL3 along with expression vectors for ERb and/or dominant
negative mutant NRF2 (NRF2DNM, 500 ng) or dominant negative
mutant Fos (FosDNM, 500 ng). Cells transfected with ERb
expression vector were also treated with TOT (107 M) for 24 h.
Cells were also transfected with PRL-SV40/Luc internal control
reporter to correct for transfection efficiency. Cell extracts were
prepared and analysed for luciferase activity using firefly and
Renilla luciferin substrate. The ratio of firefly to Renilla luciferase
activity was calculated, and reporter activity in cells transfected
with control expression vector is set at 1. Values are the
means7s.e. from three or more separate experiments. * denotes
level of significance Po0.01 versus control as determined by t-test
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while not affecting basal 8-OH-dG levels led to
inhibition of E2-induced DNA damage. These results
suggest a similar protective role as QR. While slightly
higher 8-OH-dG levels were observed in GST-Pi- or
GCSh-infected cells treated with E2 and TOT when
compared to cells treated with E2 alone, the increases
were not significant.
To determine the role of GST-Pi and GCSh in
tamoxifen protection against DNA damage, we down-
regulated GST-Pi (average 43% decrease) or GCSh
(average 46% decrease) expression using GST-Pi anti-
sense (GST-PiAS) or GCSh antisense (GCShAS) retro-
viruses, respectively. Decreases in GST-Pi or GCSh
expression led to a significant increase in basal 8-OH-dG
Figure 6 Fos, Jun, and ERb form a complex on the GST-Pi EpRE but not on the GCSh EpRE. Gel mobility shift assays were
performed using a double-stranded oligomer containing the EpRE of the human GST-Pi gene or the human GCSh gene. 32P-EpRE
GST-Pi were incubated with (a) MCF7 nuclear extracts or (b) in vitro translated Fos, Jun, NRF2, hPMC2, and/or purified
recombinant ERb in the absence or presence of 100-fold excess of unlabeled EpRE, AP1, ERE, monoclonal NRF2 antibody,
monoclonal ERb antibody, polyclonal hPMC2 antibody, or nonspecific IgG. 32P-EpRE GSCh were incubated with (c) MCF7 nuclear
extracts or (d) in vitro translated Fos, Jun, NRF2, hPMC2, and/or purified recombinant ERb in the absence or presence of unlabeled
EpRE, AP1, ERE, monoclonal NRF2 antibody, monoclonal ERb antibody, polyclonal hPMC2 antibody, or nonspecific IgG. Equal
c.p.m. and ng amounts of 32P-EpRE GST-Pi or 32P-EpRE GCSh were used in the binding reactions. The autoradiographs are
representative of three separate experiments
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levels (Figure 7c). No further increase in 8-OH-dG levels
was observed in these cells after E2 treatment. It is
possible that by decreasing GST-Pi or GCSh expression,
optimal induction of 8-OH-dG levels has already
been achieved. TOT was not able to protect against
estrogen-induced DNA damage after inhibiting GST-Pi
expression. However, GCShAS-infected cells treated
with E2 and tamoxifen had 8-OH-dG levels that were
Figure 7 GST-Pi and GCSh protect against estrogen-induced oxidative DNA damage. (a) GST-Pi or GST-PiAS retrovirus-infected
MCF7 cells were immunostained for GST-Pi. GCSh or GCShAS retrovirus-infected MCF7 cells were immunostained for GCSh.
Control retroviruses were obtained from cells transfected with the pBPSTR1 vector alone. (b) MCF7 cells were transiently infected
with GST-Pi, GCSh, or control retroviruses. (c) MCF7 cells were transiently infected with GST-PiAS, GCShAS, or control retroviruses.
The cells in (b) and (c) were then treated with vehicle (control), E2 (10
8 M), and/or the antiestrogen TOT(107 M) for 24 h and
immunostained for 8-OHdG. * denotes level of significance Po0.01 versus vehicle-treated control cells as determined by t-test. a
denotes level of significance Po0.05 versus respective control as determined by t-test. b denotes level of significance Po0.01 versus
cells infected with control retroviruses with same treatment as determined by t-test.
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significantly lower compared to what was observed with
estrogen alone. These findings suggest that while over-
expression of GST-Pi or GCSh can protect against
DNA damage, tamoxifen-mediated protection can be
attributed more to induction of GST-Pi than GCSh. It is
possible that cells are more able to compensate for the
decrease in GCSh expression. GST-Pi and QR may also
be more directly involved in inactivating estrogen
metabolites, thus decreases in their expression may have
more significant effect on 8-OH-dG levels. Of note, the
upregulation of GCSh gene transcription by estrogen
were not able to counteract estrogen-induced DNA
damage.
Discussion
We have previously performed extensive studies on the
regulation of QR transcriptional activity by ER and its
functional implications. We now report that ERb also
regulates GST-Pi and GCSh gene transcriptional
activity through the EpRE element in their promoter
region. These findings further validate our findings of
ER regulation of EpRE enhancer activity. However, our
findings also indicate mechanistic differences in the
regulation of GST-Pi EpRE and GCSh EpRE by the
ERb. While NRF2 appears to interact with ERb on
GST-Pi and GCSh EpRE, our studies support the
differential involvement of AP1 transcription factors in
ERb binding and activation of promoter activity
through the EpRE of different genes. It is possible that
the recruitment of ERb to the EpRE of different gene
promoters may be dependent on different factors.
Further functional studies support a protective role for
GST-Pi and GCSh against estrogen-induced oxidative
DNA damage.
As a major cellular antioxidant, GSH maintains
cellular redox balance and protects against reactive
oxygen species. GSH formation is controlled by the
actions of the enzymes GCS and glutathione synthetase,
with the former enzyme catalysing the rate-limiting step
(reviewed in Griffith and Mulcahy, 1999). GCS is a
holoenzyme comprised of a heavy chain (GCSh, 73 kDa)
and a light subunit (GCSl, 28 kDa). The light subunit
functions to stabilize the enzyme and is therefore termed
the regulatory chain. As the entire catalytic activity of
the enzyme resides within the heavy chain, regulation of
glutathione synthesis is closely correlated with GCSh
gene expression. GST-Pi belongs to a family of enzymes
that catalyse the conjugation of electrophilic compounds
with glutathione (reviewed in Strange et al., 2001). The
expression of antioxidative stress enzymes is regulated
by common promoter elements, the focus of this
manuscript being the EpRE/ARE. The three enzymes
that we have examined, QR, GST-Pi, and GCSh, appear
to be regulated at the transcriptional level by the ER as
well.
The EpRE in the GST-Pi promoter functions
similarly to EpREs identified in the QR in that
activation was observed with NRF2 and hPMC2. The
existence of a functional EpRE is supported by in vivo
observations that GST-Pi expression can be induced in
the livers of rats fed a diet consisting of the antioxidant
butyrated hydroxyanisole (BHA) (Cha and Heine,
1982). Our studies are also consistent with a functional
interaction between Fos and Jun and ERb in the
activation of EpRE enhancer activity. Consistent with
previous reports is our observation of the inability of
Fos and Jun, individually or together, to activate the
putative AP1 sequence in GST-Pi gene promoter
(Morrow et al., 1990). The functional interaction
between AP1 transcription factors and ER has been
well characterized and has been implicated in the
differential activation of ERa and ERb by estrogens
and antiestrogens (Paech et al., 1997). In the context of a
consensus AP1 site, ERb is activated by tamoxifen. In
the context of the QR EpRE, Jun heterodimerizes with
NRF2 and activates the QR and GST-Ya EpRE, while
Fos appears to negatively regulate the QR EpRE and
GST-Ya EpRE enhancer activity (reviewed in Dhak-
shinamoorthy et al., 2000; Jaiswal, 2000). A repressive
role for Fos is supported by the increased expression of
QR and GST-Ya EpRE in Fos knockout mice (Wilk-
inson et al., 1998). Our studies suggest that in the
context of the GST-Pi gene promoter, Fos and Jun do
not activate the GST-Pi EpRE but appear to be involved
in recruiting the ERb to the EpRE as well as ERb-
mediated transcriptional activation of EpRE.
The induction observed with antiestrogen-liganded
ERb is not due to removal of repressor/silencing activity
associated with the 105/86 region, which also
contains the NF-kB-like element. Protein factors that
bind to the repressor element at 105/86 of the GST-
Pi gene have been proposed to functionally interact
with activator elements, Fos and Jun, that bind to the
EpRE/TRE (Moffat et al., 1994). Previous reports
suggest suppression of GST-P1 gene by other nuclear
receptors by competitive binding inhibition between
Fos/Jun and RAR-RA (Xia et al., 1993). That basal
reporter activity did not increase upon removal of
the 242/83 bp region can also be attributed to
the artificial nature of our reporter constructs.
Previous reports indicate that GST-Pi expression can
be observed after stably integrating a GST-Pi minigene
that contains the putative silencer element in MCF7 cells
despite the lack of endogenous GST-Pi gene expression
(Jhaveri and Morrow, 1998a, b). This observation
supports the involvement of other alterations in DNA
or chromatin, such as methylation. A cluster of
methylation sites has been identified around the
transcriptional start site, and more dense methylation
was observed in ER-positive than ER-negative cells
(Jhaveri and Morrow, 1998a, b). Thus, in cultured
human breast cancer cell lines, GSTP1 is exclusively
expressed in ER-negative cells but is undetectable in ER-
positive cells. Epigenetic silencing through promoter
hypermethylation of GST-Pi gene is associated with
breast, prostate, and renal cancer (Esteller et al., 1998;
Singal et al., 2001).
It is possible that the expression of GST-Pi is
regulated by the balance of two factors—methylation
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and regulation by trans-acting factors. It has been
proposed that GST-Pi activation might involve prior
reversal of hypermethylation before trans-acting factors
can act on the promoter. Roles for both methylation
and trans-acting factor have been shown in the
transcriptional regulation of several genes. For example,
the methylation status of the ER gene promoters
correlated well with the suppression of the expression
of this gene in human breast cancer tissue as well as in
human breast cancer cell lines (Yoshida et al., 2000).
Methylation of ER gene promoters directly affects ER
activity in breast cancer cells, but other mechanisms,
such as loss of critical transcriptional factors, may also
be at work in some cases (Yoshida et al., 2000). The
telomerase gene is another gene that is silenced by
methylation in mammalian cells but its expression
appears to be upregulated by the ER in ovarian, breast,
and prostate cells (Kyo et al., 1999; Misiti et al., 2000;
Nanni et al., 2002). The EpRE in GST-Pi promoter
lacks CpG sequences, thus it is unlikely that CpG
methylation has a direct effect on transcription factor
binding. Moreover, methylation of binding sites does
not appear to interfere with binding and activation by
certain transcription factors (reviewed in Singal and
Ginder, 1999).
The molecular mechanism of GCSh upregulation has
been extensively studied. The transcriptional regulation
of GCSh appears to be dependent on the stimulus and
the cell type (Rahman and MacNee, 1999; Dahl and
Mulcahy, 2001). Studies by Mulcahy et al. (1997) have
suggested that basal GCSh expression in liver HepG2
cells is controlled by EpRE, which lies 3.1 kb upstream
from the start site of the gene. Transcriptional activation
of GCSh and GSCl gene promoters were reported to be
mediated by NRF2. Moreover, NRF2 is also involved in
ERb-mediated activation of GCSh EpRE. Our studies
also indicate differences in mechanism of transactivation
between the GST-Pi and GCSh EpREs in that AP-1
transcription factors are not involved in ERb-mediated
activation of GCSh gene transcription. Support for the
involvement of ER in the regulation of GCSh is a report
that phytoestrogens increase intracellular total GSH
level in vascular smooth muscle cells (Mizutani et al.,
2000).
While upregulation of QR and GST-Pi expression
and transcriptional activity is observed only with
antiestrogen-liganded ER, results from the present
studies indicate induction GCSH transcriptional
activity by estrogen-liganded ER as well. This is
reflected at the mRNA and protein level. These
observations suggest that the interaction of the estro-
gen-liganded ER with promoter-specific transcription
factors mediate transactivation from the GCSH gene
promoter.
We have now observed antiestrogen-mediated activa-
tion of EpRE enhancer activity in various promoter
contexts, the QR gene promoter (Montano et al., 1998),
GST-Ya subunit gene promoter (Montano and Katze-
nellenbogen, 1997), GST-Pi gene promoter, and GCSh
gene promoter. The induction of QR gene transcrip-
tional activity by antiestrogens was also evident in more
than one cell context. It is of note that tamoxifen has
been reported to induce an increase in the mRNA levels
of other phase II detoxification enzymes in rat liver
(Hellriegel et al., 1996). Our findings suggest that
antiestrogens by regulating the expression of numerous
proteins that contain EpREs in their regulatory regions
may afford substantial chemoprotective benefit to ER-
containing cells. This was tested by examining if GST-Pi
and GCSh can protect against estrogen-induced DNA
damage, as we have already observed for QR. We
observe that upregulation of GST-Pi and GCSh can
inhibit estrogen-induced oxidative DNA damage.
Furthermore GST-Pi, like QR, can mediate antiestrogen
inhibition of estrogen-induced DNA damage. While
we observe significant changes in oxidative DNA
damage levels with modulation of either GST-Pi and
GCSh expression, the change observed is not as
significant as TOT alone. These findings suggest
induction of more than one antioxidative stress enzymes
is involved in the prevention of DNA damage by
tamoxifen.
Based on our results, it is expected that inactivation of
GST-pi and GCSh would make breast epithelial cells
susceptible to estrogen-induced DNA damage by
compromising the ability of these enzymes to neutralize
the electrophilic intermediates generated from estrogen
metabolism. In line with the protective role of GST-Pi,
polymorphism in the GST-Pi locus has been associated
with breast cancer risk (Maugard et al., 2001; Mitrunen
et al., 2001). However, therapeutic approaches that
stimulate expression of antioxidative stress enzymes may
be a case of a ‘two-edged’ sword. Glutathione (GSH)
and related enzymes also play roles in cellular resistance
to chemotherapy (reviewed in Tew, 1994). Expression of
GST-Pi is associated with resistance to some antineo-
plastic drugs. Increased metabolic synthesis of glu-
tathione was shown in drug-resistant MCF7 (Gamcsik
et al., 2002). The increased synthetic rates of GSH in
resistant lines reflected, in part, contributions from
increased activities of GCS. An association between
certain GCSh alleles and/or drug sensitivity has also
been reported (Walsh et al., 2001), providing evidence
that suggests polymorphism of human GCSh is func-
tionally significant.
The identification of factors that regulate EpRE
enhancer activity is important not only for under-
standing the regulation QR activity in cancer cells but
also several other genes involved in antioxidant
defenses. The observation that antiestrogens can reg-
ulate the expression of several antioxidative stress
enzymes has broad implications regarding the potential
beneficial effects of antiestrogens. Antiestrogens, such as
tamoxifen and raloxifene, are routinely used for the
treatment of breast cancer based on their ability to bind
to the ER and block the proliferative effects of estrogens
on the breast. In 1998, tamoxifen became the first drug
to be approved for the reduction of risk for breast
cancer. Upregulation of antioxidative stress enzymes
may provide novel insights as to how tamoxifen
prevents breast cancer and is important for developing
newer and safer drugs.
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Cell culture media were purchased from GIBCO (Grand
Island, NY, USA). Calf serum was from Hyclone Laboratories
(Logan, UT, USA) and fetal calf serum from Atlanta
Biologicals (Norcross, GA, USA). E2, TOT, and 12-O-
tetradecanoylphorbol-13-acetate (TPA) were obtained from
Sigma Chemical Company. Custom oligonucleotides were
purchased from Genosys (Grand Island, NY, USA).
Plasmids
The reporter construct containing GST-Pi gene promoter
region 242/þ 85 has been previously described (Singal et al.,
2001). The GST-Pi-1 and GST-Pi-2 gene promoter reporter
constructs representing 124/84 and 83/33, respectively,
were constructed using the following oligonucleotides: 50-
cgcgcagcggccgccggggctggggccggcgggagtccgcgggaccctccagaag-30,
50-cgcgagcggccggcgccgtgactcagcactggggcggagcggggcgggaccaccc-30.
The oligonucleotides were annealed with their complemen-
tary oligonucleotide, gel purified and cloned into MluI/XhoI-
digested pGL3 vector. Reporter constructs containing muta-





The oligonucleotides were annealed with their complemen-
tary oligonucleotide, gel purified and cloned into MluI/XhoI-
digested pGL3 vector. To make the reporter construct
containing the GST-Pi EpRE upstream of the heterologous
thymidine kinase (tk) promoter, the oligonucleotide 50-
cgcgggcgccgtgactcagcactggg-30 was annealed with its comple-
mentary oligonucleotide, gel purified and cloned into MluI/
XhoI-digested tk-pGL3 vector. The tk-pGL3 vector was
constructed by subcloning the tk promoter containing
BamHI/BglII insert from pTZ-tk into BglII-digested pGL3.
Reporter construct containing the 50 flanking sequence
(3.8 kb) of the GCSh gene has been described previously
(Wild et al., 1999). Reporter constructs containing the GCSh
EpRE (wild type or mutant) were constructed using the
following oligonucleotides: Wild-type EpRE: 50-ctccccgtgact-
cagcgctttg- 30, Mutant EpRE: 50-ctccccgggactcagcgctttg-30.
The oligonucleotides were annealed with their complemen-
tary oligonucleotide, gel purified and cloned into MluI/XhoI-
digested tk-pGL3 vector. The AP1-luciferase reporter was
obtained from Dr Clark Distelhorst (CWRU).
Expression vectors for wild-type human ERa, ERb, and
hPMC2 have been described previously (Montano and
Katzenellenbogen, 1997; Montano et al., 2000). The expression
vectors for Fos, Jun, and AFos were obtained from Dr Clark
Distelhorst (CWRU). The expression vectors for NRF2 and
dominant negative NRF2 were obtained from Dr Jeffrey Chan
(UCSF) and Dr Jawed Alam (Alton Ochsner Medical
Foundation), respectively.
To make the retroviral vector pBPSTR1-GST-Pi (sense or
antisense), GST-Pi cDNA was released from pCI-Neo-GST-Pi
(kindly provided by Dr Rakesh Singal) by NheI/XbaI
digestion, blunted, and inserted into BamHI-digested and
blunted pBPSTR1 vector (Paulus et al., 1996). To make
pBPSTR1-GCSh (sense or antisense), cDNA containing
GCSh open reading frame was obtained using Access
RT–PCR kit from Promega (Madison, WI, USA) according
to the manufacturer’s recommendation and using the up-
stream (gcggccatggggctgctgtcccagggctcgccg) and downstream
(gaatgtctagttggatgagtcagttttacttcc) primers. The cDNA was
then cloned into the pCR-Blunt II-TOPO vector to make
pCRII-TOPO-GCSh using the Zero Blunt TOPO PCR
Cloning Kit from Invitrogen (Carlsbad, CA, USA) and
sequenced using the Sequenase Kit (United States Biochem-
icals, Cleveland, OH, USA). To construct pBSTR1-GCSh
(sense or antisense), pCRII-TOPO-GCSh was digested with
EcoRI to release GCSh coding region. The fragment was then
blunted and inserted into BamHI-digested and blunted
pBPSTR1 vector.
Tissue culture
Breast epithelial cells (MCF7 and MDA-MB-231) and PA317
amphotropic packaging cells were obtained from ATCC
(Manassas, VA, USA) and maintained according to their
recommended protocols. Prior to the experiments, breast
epithelial cells were depleted of estrogen by growth in
Improved minimal essential media minus phenol red contain-
ing 5% CDCS for 5 days before experiments.
Northern blot analyses
Total RNA was isolated using Trizol (GIBCO BRL, Rock-
ville, MD, USA). Gel purified reamplified GST-Pi and GCSh
cDNA were random primer labeled using the Ready-to-Go
DNA labeling kit from Pharmacia (Piscataway, NJ, USA) for
Northern analysis. mRNA was separated by electrophoresis,
transferred to nitrocellulose support, and hybridized with
random primer-labeled cDNA (Montano et al., 1998).
Quantitative analysis was performed on a Macintosh computer
using the public domain NIH Image program (developed at
the National Institutes of Health and available on the Internet
at http://rsb.info.nih.gov/nih-image/).
Western blot analyses
Whole cell extracts were prepared from breast epithelial MCF7
cells using M-PER (Pierce, Rockford, IL) Total protein
concentration was determined using the BCA protein assay
kit. Proteins were separated by electrophoresis on SDS–
polyacrylamide gels and transferred electrophoretically onto
nitrocellulose membranes. Blots were incubated with anti-
GST-Pi polyclonal antibody (1 : 2000 dilution; Stressgen
Biotechnologies, Victoria, BC, Canada) or GCSh polyclonal
antibody (1 : 5000 dilution, Liu et al., 1998) and goat anti-
rabbit IgG secondary antibody (1 : 40 000 dilution for GST-Pi
and 1 : 30 000 for GCSh) for detection by chemiluminescence
(ECL kit, Amersham Biosciences, Piscataway, NJ, USA).
Transfections
MDA-MB-231 were transfected as previously described
(Montano and Katzenellenbogen, 1997). Cells were seeded
for transfection in 60-mm dish in improved minimum essential
media (IMEM) minus phenol red containing 5% CDCS. Cells
at 30–50% of confluence were transfected by the CaPO4
coprecipitation method 48 h later with 2 mg reporter constructs
and 100 ng ERa or ERb expression vector. Transfection
efficiency was monitored by cotransfection with 150 ng pRL-
SV40/Luc internal control plasmid. PRL-SV40/Luc contains
cDNA (Rluc) encoding Renilla luciferase regulated by the
SV40 enhancer and early promoter elements. Carrier DNA
pTZ19R was added to adjust total DNA to 8mg. Cells
remained in contact with the precipitate for 5 h and were then
subjected to a 2.5-min glycerol shock (20% in IMEM minus
phenol red plus 5% CDCS). Cells were rinsed with HBSS and
given fresh media with or without hormones. All cells were
harvested 24 h after hormone treatment. Cells were rinsed once
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at room temperature with PBS, lysed in 100 ml 1 lysis buffer
(Dual-Luciferase Assay System, Promega Corp.), and stored at
701C until assayed. Luciferase activity was measured using
100 ml each of firefly and Renilla luciferin substrate (Promega
Corp.) per 20 ml cellular lysate in a luminometer. Data are
expressed as the ratio of firefly to Renilla luciferase activity.
Gel shift assays
Cells used to make nuclear extracts were harvested in cold
PBS. Cells were then washed in PBS twice, pelleted, and
resuspended in cold Buffer A with protease inhibitors (10mM
HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl, 1mM DTT, 0.2M
PMSF, 2mg/ml Leupeptin, 0.03 TiU/ml Aprotonin, 1 mg/ml
Pepstatin). The cells were allowed to swell on ice for 15min,
after which 62.5 ml of 10% NP-40 was added to cell suspension.
The suspension was then vortexed vigorously, pelleted and
resuspended in Buffer B (20mM HEPES pH 7.9, 25% glycerol,
0.42M NaCl, 1.5mM MgCl2, 0.2M EDTA, 1mM DTT, 0.5M
PMSF, 2mg/ml Leupeptin, 0.03TiU/ml Aprotonin, 1 mg/ml
Pepstatin). The suspension was incubated at 41C for 1 h,
pelleted, and the supernatant containing nuclear extracts were
collected and stored at 801C.
Single-stranded oligomers containing the GST-Pi EpRE 50-
gcgccgtgactcagcactggg-30 or GCSh EpRE 50-ctccccgtgact-
cagcgctttg-30 were annealed to their complement. The resultant
double-stranded oligomer was gel purified on a nondenaturing
4.5% polyacrylamide gel run in 0.5 TBE. The ability of
purified protein(s) to bind to the GST-Pi EpRE or GCSh
EpRE was analysed using gel mobility shift assays as described
previously (Montano et al., 1998). Briefly, 4mg of nuclear
extracts or 4ml (10–100 ng) of recombinant or in vitro
translated proteins were mixed with 1 ng of end-labeled
GST-Pi EpRE or GCSh EpRE oligomers in the presence of
0.4 mg/ml dIdC, 20mM HEPES, 200mM KCl, 10mM MgCl2,
2mM DTT, 2mM EDTA, 20% glycerol, 1 mg/ml BSA and
incubated at room temperature for 20min. The specificity of
binding was assessed by competition with excess unlabeled
double-stranded GST-Pi EpRE or GCSh EpRE. Protein–
DNA complexes were analysed using nondenaturing gels. The
sequence of the ERE and AP1 oligonucleotides were reporter
previously (Montano et al., 1998). ERb and NRF2 antibodies
and nonspecific IgG were obtained from Santa Cruz Biotech-
nology. hPMC2 antibody was produced for our laboratory by
Biosynthesis (Lewisville, TX, USA) using a peptide represent-
ing amino acids 170–187 of hPMC2.
In vitro transcription and translation
In vitro transcription and translation of Fos, Jun, and NRF2
were performed using the Promega TNT kit (Madison, WI,
USA). Briefly, 1 mg of cDNA was mixed with 25ml TNT rabbit
reticulocyte lysate, 2ml TNT buffer, 1ml of amino-acid
mixture, and 1ml T3 RNA polymerase (20U/ml). The final
reaction of 50 ml was incubated for 90min at 301C.
Retroviral-mediated transfection
Retroviruses were made by transfecting PA317 cells with the
pBPSTR1 plasmid alone or pBPSTR1 containing full-length
GST-Pi or GCSh cDNAs (in the sense or antisense orienta-
tion). Breast epithelial cell lines were infected with retrovirus-
containing supernatants in the presence or absence of 3mg/ml
tetracycline. The self-contained, tetracycline-regulated retro-
viral vector pBPSTR1 contains both the response unit,
composed of tetracycline-resistance operon regulatory elements
(tetO) within a minimal CMV promoter, and the regulator unit,
encoding the tTA protein (the tetracycline repressor fused to
the transactivator protein VP16) (Paulus et al., 1996). Gene
expression is inhibited by tetracycline, which binds the
transactivator protein tTA, causing it to dissociate from the
tetO minimal CMV promoter. Changes in protein expression
were verified by immunofluorescence staining.
Immunofluorescence staining of breast cells
Cells were immunostained and quantified as previously
described (Bianco and Montano, 2002; Bianco et al., 2003).
Cells grown on coverslips were fixed in 4% paraformaldehyde.
After blocking with 5% normal goat serum, samples were
incubated with GST-Pi or GCSh antibody (1 : 100 dilution)
and goat, anti-rabbit IgG Alexa 488 fluorescent secondary
antibody (Molecular Probes). As a negative control, duplicate
sections were immunostained with nonspecific rabbit IgG or
with secondary antibody alone. Semiquantitation analysis was
performed on a MacIntosh computer using Adobe Photoshop
6.0 software. The mean luminosity of 15–20 cells from each
experiment was measured and averaged with background
subtracted out from each field.
Immunocytochemistry for 8-OHDG in breast cells
8-OHdG levels were measured and quantified as previously
described (Bianco et al., 2003). Cells grown on coverslips were
fixed in methacarn (methanol/chloroform/acetic acid, 6 : 3 : 1)
for 1 h at RT. Endogenous peroxidase activity in the cells was
eliminated by a 30min incubation with 3% H2O2 in methanol,
and nonspecific binding sites were blocked in a 15min
incubation with 10% normal goat serum in Tris-buffered
saline (150mM Tris-HCl and 150mM NaCl, pH 7.6). The cells
were then pretreated with proteinase-K (20 mg/ml in PBS, pH
7.4 for 15min at RT; Boehringer Mannheim, Indianapolis, IN,
USA). To detect oxidized nucleosides, we used the anti-8-oxo-
dG monoclonal antibody 1F7 (1 : 100; Trevigen, Gaithersburg,
MD, USA). As a negative control, cells were incubated
without the primary antibody. Immunostaining was developed
by the peroxidase–antiperoxidase procedure.
Immunoreactivity was evaluated by measuring optical
density (OD). The OD was assessed using a Carl Zeiss
Axiocam digital camera with a KS300 Imaging System
quantitation program. OD of manually outlined cells were
measured. Five cells in three adjacent fields were measured and
the background OD was subtracted from each. Each experi-
ment was performed two or more times and results were
measured under the same optical and light conditions.
Statistical analysis was performed using the Students t-test.
Statistical analysis
Data were evaluated by analysis of variance and tested for
statistical significance using the Student’s t-test.
Abbreviations
ERb, estrogen receptor b; ERa, estrogen receptor a; E2, 17b-
estradiol; TOT, trans-hydroxytamoxifen; QR, quinone reduc-
tase; GST-Pi, glutathione S-transferases Pi; GCSh, gamma-
glutamylcysteine synthetase heavy subunit; ARE/EpRE, anti-
oxidant/electrophile response element ; 8-OHdG, 8-hydroxy-
deoxyguanine.
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